Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in recurrent malignant lymphoma
NCT03316144Phase 1Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jul 2017
- Primary completion
- Sep 2018
- Countries
- 1
01
Overview
Phase 1, open-label trial of toripalimab in malignant lymphoma (3 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoint: Number of participants with treatment-related adverse events at 6 months. Started Jul 2017; status: completed.
02
Drugs
toripalimab
03
Conditions
malignant lymphoma
Beyond the preview
Go deeper on NCT03316144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03316144.